Literature DB >> 11443581

A cross-sectional study of SEN virus in liver transplant recipients.

E M Yoshida1, A K Buczkowski, A Giulivi, S Zou, L A Forrester.   

Abstract

A new DNA virus, referred to as SEN virus (SEN V), has been isolated and is associated with blood-product transfusion and possibly Non A to Non E hepatitis. We performed a cross-sectional analysis of SEN V in liver transplant recipients at our center. Polymerase chain reaction was used to test for 2 genotypes of SEN V (SEN V:C/H and SEN V:D) in 58 unselected patients. Comparisons were made between SEN V--positive and SEN V--negative groups in terms of age, time posttransplantation, indications for transplantation, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and cytomegalovirus and Epstein-Barr virus status. Thirty of 58 transplant recipients (51.7%) were SEN V positive; 15.5% were positive for SEN V:C/H, 24.1% for SEN:D, and 12.1% for both strains. No significant differences were found based on primary indication for transplantation, including hepatitis C virus (HCV). Of the 14 of 21 patients with HCV seropositivity and HCV reinfection, 79% were positive for SEN V (P =.02). There was no difference in the proportion of patients with abnormal serum ALT and/or AST levels. A trend for the SEN V--positive group to have a greater mean ALT level (82 v 41 U/L; P =.067) was attributable to the subgroup with HCV recurrence because there was no difference in mean ALT levels (34.9 v 34.5 U/L; P =.968) in non--HCV-infected transplant recipients. Even in the subgroup (n = 14) with recurrent HCV, there was no statistically significant difference in mean ALT levels (140 v 105 U/L; P =.665). Age and cytomegalovirus or Epstein-Barr virus status were not significantly different between the 2 groups, but a significant difference in posttransplantation time was noted (16.8 v 32 months; P =.021). We conclude that SEN V is common among liver transplant recipients but does not appear to cause graft dysfunction as an isolated agent. There is a suggestion that SEN V may be associated with HCV recurrence, but we did not detect biochemical differences attributable to SEN V.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443581     DOI: 10.1053/jlts.2001.24643

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  2 in total

1.  Effect of SEN virus coinfection on outcome of lamivudine therapy in patients with hepatitis B.

Authors:  Dong Xu; De-Ying Tian; Zhen-Gang Zhang; Hong-Yun Chen; Pei-Hui Song
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

2.  Detection of SEN virus in the general population and different risk groups in Slovakia.

Authors:  I Schréter; P Kristian; P Jarcuska; S Porubcin; L Siegfried; E Birosová; A Rajnic; A Gocalová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.